Immunocore stock rises as Q1 results top estimates

Published 07/05/2025, 16:20
Immunocore stock rises as Q1 results top estimates

Investing.com -- Immunocore Holdings plc (NASDAQ:IMCR) shares gained 4.1% after the biotechnology company reported first quarter earnings and revenue that surpassed analyst expectations, driven by strong sales of its lead product KIMMTRAK.

The company posted Q1 adjusted earnings per share of $0.10, beating the analyst consensus estimate of -$0.39 by $0.49. Revenue came in at $93.9 million, topping expectations of $86.1 million.

KIMMTRAK net product sales grew 33% YoY to $93.9 million in Q1, with $56.6 million generated in the U.S., $32.8 million in Europe, and $4.5 million in other international regions. The company cited increased demand and new country launches as key growth drivers.

"We are thrilled to have achieved strong revenue performance in Q1, marked by year-over-year growth of 33%. This reflects our unwavering dedication to making KIMMTRAK accessible to patients who need it," said CEO Bahija Jallal.

Immunocore reported a net income of $5.0 million for the quarter, compared to a net loss of $24.4 million in the same period last year. Research and development expenses were $56.5 million, down slightly from $57.5 million a year ago.

The company ended the quarter with $837.0 million in cash, cash equivalents and marketable securities. Immunocore reiterated it is on track to complete enrollment for its Phase 3 TEBE-AM trial in the first half of 2026 and select the dose for its Phase 3 PRISM-MEL-301 trial in the second half of 2025.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.